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Immunochip Analyses of Epistasis in Rheumatoid
Arthritis Confirm Multiple Interactions within MHC
and Suggest Novel Non-MHC Epistatic Signals
Wen-Hua Wei, Chia-Yin Loh, Jane Worthington, and Stephen Eyre
ABSTRACT. Objective. Studying statistical gene-gene interactions (epistasis) has been limited by the difficulties
in performance, both statistically and computationally, in large enough sample numbers to gain suffi-
cient power. Three large Immunochip datasets from cohort samples recruited in the United Kingdom,
United States, and Sweden with European ancestry were used to examine epistasis in rheumatoid
arthritis (RA).
Methods. A full pairwise search was conducted in the UK cohort using a high-throughput tool and
the resultant significant epistatic signals were tested for replication in the United States and Swedish
cohorts. A forward selection approach was applied to remove redundant signals, while conditioning
on the preidentified additive effects.
Results.We detected abundant genome-wide significant (p < 1.0e-13) epistatic signals, all within the
MHC region. These signals were reduced substantially, but a proportion remained significant (p <
1.0e-03) in conditional tests. We identified 11 independent epistatic interactions across the entire
MHC, each explaining on average 0.12% of the phenotypic variance, nearly all replicated in both
replication cohorts. We also identified non-MHC epistatic interactions between RA susceptible loci
LOC100506023 and IRF5 with Immunochip-wide significance (p < 1.1e-08) and between 2 neigh-
boring single-nucleotide polymorphism near PTPN22 that were in low linkage disequilibrium with
independent interaction (p < 1.0e-05). Both non-MHC epistatic interactions were statistically repli-
cated with a similar interaction pattern in the US cohort only. 
Conclusion. There are multiple but relatively weak interactions independent of the additive effects
in RA and a larger sample number is required to confidently assign additional non-MHC epistasis. 
(J Rheumatol First Release February 15 2016; doi:10.3899/jrheum.150836)
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
affecting about 1% of the population worldwide1, which if
left untreated can lead to progressive synovial joint
destruction and subsequent movement disability. Prognosis
and treatment at the early stage of the disease are critical to
prevent or delay irreparable joint and bone damage2. It is
therefore important to understand the pathogenesis of RA and
the underlying molecular mechanisms to aid development of
effective diagnostic tools and treatments.
RA is a complex disease resulting from the interplay of
genetic and environmental risk factors. More than 50% of the
RA disease risk in twins can be explained by the genetic
factors3. To date, over 100 RA risk loci have been discovered
as a result of genome-wide association studies (GWAS)4,5.
GWAS primarily consider additive genetic effects and rely
on large sample sizes and high-density single-nucleotide
polymorphism (SNP) markers to detect loci with moderate
or weak effects. Despite the success to date in identifying risk
loci for RA, mostly through metaanalysis of multiple cohorts,
about 40% of the genetic component of susceptibility remains
unaccounted for. One possible explanation for this is the
failure to consider nonadditive effects such as dominance6
and statistical gene-gene interactions (epistasis)7,8.
So far, analyses of epistasis in human complex traits have
been limited by the difficulties, both statistically and compu-
tationally, in doing so in large enough sample numbers to gain
sufficient power, and as a result only a handful of epistatic
interactions have been firmly identified9. Such epistatic inter-
actions each carry a moderate effect and thus explain only
limited genetic variation of the complex trait studied, but
appear essential in modifying the functions of the interacting
genes7,8,9. In RA, previous studies10,11 have reported abun -
dant epistatic interactions between SNP mapping to the MHC
region without considering the additive effects of the major
susceptibility loci within the region. When adjusting for the
effects of the well-established HLA-shared epitope (i.e.,
HLA-DRB1 alleles encoding a 5 amino acid sequence
motif)1,12, the MHC interactions were hugely reduced, but 2
interactions between HLA class II genes remained statisti-
cally significant, indicating there exist moderate epistatic
interactions independent of the HLA additive effects13.
Indeed, focusing on only the HLA-DRB1 locus and using
high-resolution imputation in a large combined RA cohort,
Lenz, et al14 revealed 7 interactions between HLA-DRB1
haplotypes that jointly explained an additional 0.5% of the
phenotypic variance. Detection of epistasis involving
non-MHC loci in RA has been rather challenging10,13. An
epistatic interaction between BANK1 and BLK in RA was
reported from a candidate gene study15 following the finding
of BANK1-BLK interaction in systemic lupus erythematosus
(SLE) with some protein-protein interaction evidence16. In
both cases, the reported interaction was just nominally signifi -
cant (1.0e-02 < p < 5.0e-02), suggesting it might not be
detectable at the genome-wide level.
The power of detection of epistasis is a function of the
interaction effect size, sample size, and the linkage disequi-
librium (LD) between markers and the causal variants at both
loci9. While interaction effects are probably moderate/weak,
increasing the sample size and marker density is the most
effective approach to increase power. Besides, examining
local interactions between SNP closely located but with low
LD (r2 < 0.2) could increase the power of detection of
missing variants and/or functional interactions17,18. The use
of the Immunochip, a custom array of about 200,000 SNP
specifically designed for the fine mapping of a set of
immune-mediated disease loci19, has resulted in the gener-
ation of genetic data on much larger numbers of samples for
RA and other diseases than was previously achieved through
the use of genome-wide arrays and has allowed the
refinement of the association signal for multiple autoimmune
disease loci4. A study of epistasis in primary biliary cirrhosis
in a large Immunochip dataset20 suggests the potential to
detect non-MHC interactions.
Here we used 3 large Immunochip datasets of cohort
samples recruited in the United Kingdom, United States, and
Sweden, to examine epistasis in RA. We performed an
exhaustive pairwise search for epistatic signals in the UK
cohort and used the other 2 cohorts to test for replication of
any significant signals. The biological plausibility of any
statistically significant interactions was also investigated.
MATERIALS AND METHODS 
Subjects, genotyping, and quality control. We used 3 large cohort samples
from the Rheumatoid Arthritis Consortium International for Immunochip
that were recruited in the United Kingdom (RACI-UK), United States
(RACI-US), and Sweden (RACI-SE, i.e., Swedish Epidemiological
Investigation of Rheumatoid Arthritis). The 3 cohorts have been described
in detail elsewhere4,5. Briefly, all patients with RA fulfilled the 1987 criteria
of the American College of Rheumatology21; all participants provided
written informed consent as approved by a corresponding ethical committee
and were genotyped by Immunochip in accordance with Illumina protocols.
Only samples with European origin and autosomal SNP were used. SNP
genomic locations were in the GRCh38/hg38 version throughout and the
MHC was referred to as between 28.7 to 34.0 Mb on chromosome 6.
For each cohort, quality control was conducted using PLINK22 according
to the following criteria: SNP minor allele frequency > 0.01, SNP call rate
> 0.95, sample call rate > 0.99, and deviation from Hardy–Weinberg
equilibrium p < 1.0e-04. Then the GCTA software23 was used first to
compute the genomic relationship matrix (GRM) and then to remove any
related samples through the polygenic prediction procedure using a GRM
relatedness threshold of 0.15 recommended for Immunochip24. In total, we
had 12,266 unrelated samples (3856 cases and 8410 controls, 59.3% women)
and 124,453 SNP in the RACI-UK, 4658 samples (2532 cases and 2126
controls, 70.5% women) and 118,678 SNP in the RACI-US, and 4682
samples (2750 cases and 1932 controls, 71.6% women) and 123,315 SNP
in the RACI-SE in subsequent analyses.
Statistical analysis. PLINK was used to perform a GWAS in the RACI-UK
while fitting sex as covariates in a logistic regression model. The consensus
genome-wide significance threshold of 5.0e-08 was applied.
A 2-step approach was used to detect epistasis. First, BiForce25 was used
to perform a full pairwise screening without correction for covariates in the
RACI-UK and retained all possible epistatic pairs of SNP with an interaction
p value (pint) < 1.0e-05. The retained SNP pairs were adjusted for sex in a
full logistic regression model using an R package GenABEL26, and assessed
using the adjusted pint values hereafter. The genotypic model of epistasis
was applied in both steps where interaction was tested with 4 degrees of
freedom as previously described27. A recommended threshold of 1.0e-139
was adopted to claim genome-wide significant epistatic SNP pairs. We also
adopted an Immunochip-wide 5% significance threshold of 1.1e-08 based
on the estimate of 3000 effective number of SNP24. In addition, local inter-
actions were extracted if both SNP were located on the same chromosome
and within a distance < 1 Mb, with pint < 1.0e-05 and r2 < 0.217.
A forward selection approach was applied iteratively to the MHC
genome-wide significant signals to identify first the independent GWAS SNP
as the additive background and then independent epistatic SNP pairs condi-
tioning on the additive background. Within each iteration, the most
associated SNP or SNP pair (i.e., with the lowest conditional p/pint value)
was selected and fixed in the logistic regression model fitting the covariates
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as well as any prefixed SNP or SNP pairs. The conditional p or pint values
for the remaining SNP or SNP pairs were then calculated. The forward
selection process terminated when no more SNP (or SNP pairs) were signifi -
cant (i.e., conditional p/pint > 5.0e-02). The forward selection approach was
also taken to identify independent non-MHC SNP pairs when multiple pairs
of SNP were likely to be describing the same interaction. Variance explained
by the selected epistatic SNP pairs was calculated using a full logistic
regression model fitting all the covariates and independent SNP and SNP
pairs.
The SNP pairs identified in the RACI-UK were tested for replication in
the RACI-US and RACI-SE using the logistic regression model adjusted for
sex and considered to be directly replicated if both epistatic SNP had
genotype data available and with pint < 5.0e-02. Statistically replicated
epistatic SNP pairs were further examined for interaction patterns/directions
in both cohorts, based on OR and their 95% CI estimated by fitting a logistic
regression model that included sex as covariates and each of the 9 possible
2-locus genotypes and using the first homogeneous 2-locus genotype as the
reference that by definition had an OR of 1. The OR and CI were plotted
using the R package plotrix. The replicated epistatic pairs of SNP were
annotated to the closest biologically plausible genes.
RESULTS
The conventional GWAS analysis of the RACI-UK revealed
1746 genome-wide significant SNP (p < 5.0e-08), of which
the vast majority were within the MHC region. Following the
forward selection approach, 20 independent SNP were
identified, of which 16 were mapped to the MHC region, 2
to PTPN22, 1 to TNFAIP3, and the remaining 1 to ANKRD55
(Supplementary Table 1, available online at jrheum.org).
The full pairwise scan detected 29,921 epistatic pairs of
SNP that were genome-wide significant (i.e., pint < 1.0e-13),
all within the MHC region. Conditioning on the additive
background of the 20 independent SNP, 132 of these
genome-wide significant SNP pairs had a conditional pint <
1.0e-03 (and 2807 additional SNP pairs with a conditional
pint between 1.0e-03 and 5.0e-02), indicating that there were
indeed epistatic signals within the MHC independent of the
additive background. Further forward selection of the 132
SNP pairs resulted in 11 independent epistatic signals repre-
senting 3 types of interactions involving either both or 1 or
no SNP with genome-wide significant additive effects (Table
1). The 11 independent epistatic pairs of SNP each had a
direct replication in both replication cohorts (except for
rs805285-rs532098 in the RACI-US), suggesting existence
of multiple epistatic interactions across the entire MHC.
Conditioning on the additive background that explained
10.8% of the phenotypic variance, the 11 independent pairs
of SNP jointly explained an additional 1.7% of the pheno-
typic variance on the observed scale of which 1.4% by inter-
actions only, suggesting that these interaction effects were
not negligible jointly, but weak individually (i.e., on average
explained 0.12% of the phenotypic variance).
We found that 50 non-MHC SNP pairs exceeded the
Immunochip-wide significance threshold of 1.1e-08
(Supplementary Table 2, available online at jrheum.org), of
which only epistatic interactions between rs6425230
(LOC100506023) and rs17340646 (near IRF5) and between
rs17547025 (LOC101929036) and rs9806697 (near SEMA6D)
were directly replicated only in RACI-US and RACI-SE,
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Table 1. Independent epistatic SNP pairs within the MHC region adjusted for the preidentified additive background in the RACI-UK and statistical replication
in the RACI-US and RACI-SE*.
SNP1 Pos1 Gene1 SNP2 Pos2 Gene2 LD pSNP1_UK pSNP2_UK pint_UK pint_US pint_SE pint_cond pint_final
rs805286 31711530 LY6G6E rs405875 32247411 Near NOTCH4 0.00 2.5e-03 1.5e-36 3.0e-16 2.6e-03 4.2e-05 1.3e-05 1.3e-05
rs154977 32932241 Near HLA-DMB rs1042337 32937203 HLA-DMB 0.03 5.2e-22 4.4e-02 1.4e-15 4.4e-05 1.5e-02 1.5e-04 3.9e-04
rs2229094 31572779 LTA rs2844455 31901896 C2 0.00 1.3e-02 4.4e-21 1.2e-17 7.8e-04 4.8e-04 3.8e-05 1.4e-04
rs3131009 31131055 PSORS1C1 rs9267845 32225921 Near NOTCH4 0.00 5.2e-02 8.1e-08 3.9e-15 5.2e-07 3.2e-04 5.4e-04 1.5e-04
rs9264868 31303824 HLA-C ~ HLA-B rs443198 32222629 NOTCH4 0.03 7.4e-01 9.5e-01 1.0e-18 4.4e-02 3.2e-03 1.4e-04 6.1e-04
rs9275653 32718088 Near HLA-DQA2 rs2006165 32761010 HLA-DQB2 0.11 8.5e-01 6.3e-02 6.2e-29 2.3e-06 1.1e-03 2.2e-04 2.6e-04
rs805285 31711688 Near LY6G6E rs532098 32610275 HLA-DRB1 ~ 0.01 4.9e-02 6.2e-28 5.2e-15 > 0.05 4.2e-02 4.9e-05 4.5e-04
HLA-DQA1
rs9501398 32234820 Near NOTCH4 rs3177928 32444658 HLA-DRA 0.05 2.3e-01 2.3e-06 4.4e-14 5.5e-07 8.9e-03 5.4e-04 3.3e-03
rs9469220 32690533 Near HLA-DQB1 rs3104407 32714675 HLA-DQB1 ~ 0.02 9.3e-03 7.1e-26 5.1e-21 4.4e-21 5.6e-06 7.4e-04 2.6e-03
HLA-DQA2
rs2395471 31272915 Near HLA-C rs9268658 32442939 HLA-DRA 0.00 2.5e-04 7.8e-39 4.1e-14 8.1e-13 3.5e-04 8.1e-04 5.6e-03
rs5000634 32695787 HLA-DQB1 ~ rs3104407 32714675 HLA-DQB1 ~ 0.24 4.4e-51 7.1e-26 5.0e-15 6.6e-04 6.9e-04 7.2e-04 2.9e-02
HLA-DQA2 HLA-DQA2
* The epistatic SNP pairs in the order appeared in the forward selection process. SNP in bold face are genome-wide significant in the GWAS. SNP: single-
nucleotide polymorphism; RACI: Rheumatoid Arthritis Consortium International for Immunochip; UK: United Kingdom; US: United States; SE: Sweden;
SNP1 (SNP2): the first (second) epistatic SNP; Pos1 (Pos2): the base pair position of SNP1 (SNP2); Gene1 (Gene2): gene mapped by SNP1 (SNP2) – if inter-
genic annotated as the nearest (with “near”) or flanking genes separated by “~”; LD: linkage disequilibrium in r2; pSNP1_UK (pSNP2_UK): the p values of SNP1
(SNP2) in the logistic regression model fitting genotypes of the 2 SNP and their interactions without adjusting for the MHC additive background; pint_UK: the
interaction p values from the pairwise scan of the RACI-UK without adjusting for the additive background; pint_US: the interaction p values from replication
tests in the RACI-US without considering the additive background; pint_SE: the interaction p values from replication tests in the RACI-SE without considering
the additive background; pint_cond: the interaction p values when conditioning on the additive background in the RACI-UK; pint_final: the interaction p values in
the final model fitting the additive background and all the independent pairs in the RACI-UK; > 0.05: interaction p value of the replication test greater than
5.0e-02; GWAS: genome-wide association studies.
respectively (Table 2). Conditioning on the additive
background, the 2 epistatic pairs explained 0.28% and 0.32%
of the phenotypic variance in the RACI-UK, respectively, of
which the vast majority (i.e., 0.22% and 0.27%, respectively)
was contributed by interactions. Nonetheless, only rs6425230
(LOC10050-6023)-rs17340646 (near IRF5) had a similar
interaction pattern in the replication cohort (Figure 1).
We also found 55 non-MHC SNP pairs involved in local
interactions (Supplementary Table 3, available online at
jrheum.org), of which epistatic interaction between
rs2488457 (near PTPN22) and rs17032048 (near HIPK1)
was directly replicated only in the RACI-US, and that
between rs12711109 (near KIAA1109) and rs10518402
(IL21-AS1) was directly replicated only in the RACI-SE
(Table 2). Conditioning on the additive background, these 2
epistatic SNP pairs explained 0.11% and 0.23% of pheno-
typic variance in the RACI-UK, mostly by interactions (i.e.,
0.1% and 0.19%), respectively. The rs2488457 (near
PTPN22)-rs17032048 (near HIPK1) pair had a similar inter-
action pattern in the replication cohort, whereas the
rs12711109 (near KIAA1109) and rs10518402 (IL21-AS1)
pair did not share an interaction pattern (Figure 1).
DISCUSSION
Here we present results from a large analysis of epistatic
interactions in RA. Compared with previous studies that used
a relatively small sample size (e.g., with < 2000 cases and
3000 controls) and a GWAS array10,11,13, our study had a
much increased sample size (i.e., 3856 cases and 8410
controls) and genotype data from the high-density Immuno -
chip, allowing the identification of many more genome-wide
significant interactions within the MHC region. Conditioning
on the additive background, we confirmed that most of these
interaction signals mirrored the strong HLA additive effects,
but in addition there were 11 independent interactions each
with a moderate/weak effect that were statistically replicated
in 2 independent cohorts. These results indicate that, in
addition to the recently confirmed epistasis within the
HLA-DRB1 locus14, the entire MHC region contains an
increased level of complexity, with additional associations to
disease risk, over and above the multiple independent signals
previously reported. Nevertheless, caution is recommended
in interpreting the 11 independent epistatic pairs given that
the resolution provided by Immunochip SNP is insufficient
to identify the MHC diversity and the additive background
was derived imperfectly. Further work is needed to finely
map the MHC epistatic signals based on high-resolution
imputation and large samples as demonstrated elsewhere14.
The large Immunochip cohort RACI-UK also enabled us
to detect non-MHC epistatic interactions (Table 2). Based on
the Immunochip-wide significance threshold, we identified
the rs6425230 (LOC100506023)-rs17340646 (near IRF5)
epistatic pair that was directly replicated in the RACI-US
(Table 2) and with a similar interaction pattern (Figure
1A). Both LOC100506023 and IRF5 are known
RA-susceptible loci identified from a GWAS meta -
analysis5. Interestingly, IRF5 was previously found to be
an interacting locus with moderate interactions in
autoimmune diseases SLE28,29,30 and primary biliary
cirrhosis20. From the local interactions in the RACI-UK
(Supplementary Table 3, available online at jrheum.org),
we identified the rs2488457 (near PTPN22)-rs17032048
(near HIPK1) epistatic pair that was also directly replicated
in the RACI-US with a similar interaction pattern (Table 2
and Figure 1C). We showed that this local interaction was
greatly reduced but remained nominally significant when
conditioning on the predefined additive background
including the well-known PTPN22 variant marked by
rs2476601 (Supplementary Table 1, available online at
jrheum.org). While the biological function of the epistatic
pair is unclear, the result at least suggested that there could
be independent epistasis involved in regulating PTPN22,
although the epistasis was relatively weak and not directly
replicated in the second replication cohort RACI-SE.
Nonetheless, we reported only SNP interactions that were
directly replicated (i.e., both SNP are genotyped and are inter-
acting) with a similar interaction pattern in an independent
cohort. As a result of this stringent criteria, we could have
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Table 2. Non-MHC epistatic pairs of SNP in the RACI-UK and statistical replication in the RACI-US and RACI-SE.
SNP1 Chr1 Pos1 Gene1 SNP2 Chr2 Pos2 Gene2 LD pSNP1_UK pSNP2_UK pint_UK pint_US pint_SE pint_cond
rs6425230 1 173418899 LOC100506023 rs17340646 7 129082460 Near IRF5 0.00 2.8e-01 7.2e-02 4.9e-09 3.6e-02 > 0.05 7.5e-07
rs17547025 12 102932492 LOC101929036 rs9806697 15 47778596 Near SEMA6D 0.00 5.0e-02 2.1e-01 8.2e-09 > 0.05 2.6e-02 2.8e-08
rs2488457 1 113872746 PTPN22 rs17032048 1 113984753 HIPK1 0.11 3.0e-11 5.8e-08 6.9e-06 1.4e-05 > 0.05 1.4e-02
rs12711109 4 122091415 Near KIAA1109 rs10518402 4 122633635 IL21-AS1 0.04 2.4e-02 3.4e-01 2.5e-06 > 0.05 2.8e-02 8.8e-06
SNP: single-nucleotide polymorphism; RACI: Rheumatoid Arthritis Consortium International for Immunochip; UK: United Kingdom; US: United States; SE:
Sweden; SNP1 (SNP2): the first (second) epistatic SNP; Chr1 (Chr2): the chromosome of SNP1 (SNP2); Pos1 (Pos2): the base pair position of SNP1 (SNP2);
Gene1 (Gene2): gene mapped by SNP1 (SNP2) – if intergenic annotated as the nearest (with “near”); LD: linkage disequilibrium in r2; pSNP1_UK (pSNP2_UK):
the p values of SNP1 (SNP2) in the logistic regression model fitting genotypes of the 2 SNP and their interactions; pint_UK: the interaction p values from the
pairwise scan of RACI-UK without adjusting for the additive background; pint_US: the interaction p values from replication tests in the RACI-US without
considering the additive background; pint_SE: the interaction p values from replication tests in the RACI-SE without considering the additive background;
pint_cond: the interaction p values when conditioning on the additive background in the RACI-UK; > 0.05: interaction p value of the replication test greater than
5.0e-02.
failed to detect additional non-MHC interactions that are not
directly but indirectly replicated through proxies of the
epistatic SNP. Besides, the sample size in either the RACI-US
or RACI-SE was about 50% smaller than that in the discovery
cohort and thus could have limited replication results. Further,
special cohort structures, e.g., matched cases and controls used
only in the RACI-SE4, could influence calculation OR and
subsequently interaction patterns (Figure 1).
We also tested statistical interactions between the
genome-wide significant GWAS SNP in the RACI-UK, but
found no significant epistasis beyond the MHC region, which
is in agreement with the results by Liu, et al13 that used an
allelic model instead (i.e., concerning only SNP additive
effects and additive-additive interaction). However, the
epistatic interaction between HLA-DQA2 and HLA-DQB2
reported by Liu, et al13 was only marginally significant (i.e.,
pint = 1.9e-02 for rs9275390-rs10807113 in the genotypic
model) when adjusting for the additive background in the
RACI-UK and thus was not among the 11 independent MHC
epistatic signals (Table 1). This discrepancy highlights the
limitation of the allelic model in studying epistasis and the
importance of applying proper adjustment of preidentified
additive effects. In addition, we found that the reported
epistatic interactions between ERAP1 and HLA-C in
psoriasis8 and between ERAP1 and HLA-B*51 in Behçet
disease31 did not reach the nominal significance level in the
RACI-UK (the ERAP1 and HLA-B27 interaction in anky -
losing spondylitis7 was not tested because of unavailable
genotype data of the epistatic SNP rs4349859), suggesting
RA may have different regulatory mechanisms.
Our results indicate that epistasis may exist in regulating
complex diseases such as RA, but is unlikely to explain much
genetic variance (i.e., with small effect sizes) and hence
requires a large sample size to detect conclusively. These
results provide fresh evidence to support the theoretical
prediction of low amounts of epistatic variance in complex
traits in outbred populations32 that could still be important to
understand the underlying regulatory mechanisms. However,
5Wei, et al: Epistatic interactions in RA
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Figure 1. Statistical interaction patterns of 4 directly replicated epistatic pairs of SNP based on or estimated for each of the 9 joint
SNP genotypes in the discovery (solid line) and replication (dash line) cohorts. A. rs6425230 (LOC100506023)-rs17340646 (near
IRF5) replicated in the RACI-US. B. rs17547025 (LOC101929036)-rs9806697 (near SEMA6D) replicated in the RACI-SE. C.
rs2488457 (near PTPN22)-rs17032048 (near HIPK1) replicated in the RACI-US. D. rs12711109 (near KIAA1109)-rs10518402
(IL21-AS1) replicated in the RACI-SE. Bars represent 95% CI calculated from the standard errors of the estimates of the genotype
variables in the logistic regression model used to calculate genotypic OR. SNP: single-nucleotide polymorphism; RACI: Rheumatoid
Arthritis Consortium International for Immunochip; US: United States; SE: Sweden.
our study does not provide a genome-wide view of epistasis
in RA because of the use of Immunochip, and the results may
be slightly conservative because of the stringent replication
criteria and the inclusion of all patients with RA, irrespective
of disease heterogeneity1.
Taking advantage of increased samples and high density
SNP offered by Immunochip, we confirmed the existence of
epistatic interactions with the MHC region and suggested
novel non-MHC interactions with moderate interaction
effects but plausible biological interests. Further work is
required to validate the identified epistatic interactions
functionally.
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